sur GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Secures €2.8 Million Financing
On November 1, 2024, GenSight Biologics announced a €2.8 million financing from existing investors. The biotech company reserved this capital increase for specialized investors via a new shares issuance, each share with an attached warrant at an offering price of €0.3513. This move aims to address a slight delay in the resumption of the French Early Access Program expected in December 2024.
The funds are set to extend the company's cash runway by 12 months, although without the proceeds, the company could only cover obligations until mid-November 2024. As of September end, it reported €3.4 million in cash, with a 12-month net cash requirement estimated at €37 million. The capital increase was completed without shareholders' preferential rights, in compliance with French corporate regulations.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de GENSIGHT BIOLOGICS S.A.